BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9094677)

  • 1. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.
    Melero I; Singhal MC; McGowan P; Haugen HS; Blake J; Hellstrom KE; Yang G; Clegg CH; Chen L
    J Virol; 1997 May; 71(5):3998-4004. PubMed ID: 9094677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E7-specific cytotoxic T cell tolerance in HPV-transgenic mice.
    Borchers A; Braspenning J; Meijer J; Osen W; Gissmann L; Jochmus I
    Arch Virol; 1999; 144(8):1539-56. PubMed ID: 10486109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
    Herd K; Fernando GJ; Dunn LA; Frazer IH; Lambert P; Tindle RW
    Virology; 1997 Apr; 231(1):155-65. PubMed ID: 9143315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development.
    Routes JM; Ryan S; Li H; Steinke J; Cook JL
    Virology; 2000 Nov; 277(1):48-57. PubMed ID: 11062035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease.
    Frazer IH; Leippe DM; Dunn LA; Liem A; Tindle RW; Fernando GJ; Phelps WC; Lambert PF
    Cancer Res; 1995 Jun; 55(12):2635-9. PubMed ID: 7540107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
    Street MD; Doan T; Herd KA; Tindle RW
    Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
    Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
    J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.
    Chen L; Mizuno MT; Singhal MC; Hu SL; Galloway DA; Hellström I; Hellström KE
    J Immunol; 1992 Apr; 148(8):2617-21. PubMed ID: 1313847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy.
    Thornburg C; Boczkowski D; Gilboa E; Nair SK
    J Immunother; 2000; 23(4):412-8. PubMed ID: 10916750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
    Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16.
    Sarkar AK; Tortolero-Luna G; Nehete PN; Arlinghaus RB; Mitchell MF; Sastry KJ
    Viral Immunol; 1995; 8(3):165-74. PubMed ID: 8833270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes.
    Doan T; Chambers M; Street M; Fernando GJ; Herd K; Lambert P; Tindle R
    Virology; 1998 May; 244(2):352-64. PubMed ID: 9601506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
    Bauer M; Wagner H; Lipford GB
    Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.
    Cassetti MC; McElhiney SP; Shahabi V; Pullen JK; Le Poole IC; Eiben GL; Smith LR; Kast WM
    Vaccine; 2004 Jan; 22(3-4):520-7. PubMed ID: 14670335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice.
    Yang JT; Liu CZ; Domer P; Iannaccone P
    Cancer Detect Prev; 1998; 22(5):405-15. PubMed ID: 9727621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice.
    Gulliver GA; Herber RL; Liem A; Lambert PF
    J Virol; 1997 Aug; 71(8):5905-14. PubMed ID: 9223480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.